01 July, 2017
(NASDAQ:ARNA) have received a consensus rating of "Buy" from the nine ratings firms that are covering the stock, Marketbeat.com reports. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. They now have a United States dollars 5 price target on the stock.
ICPT has been the subject of a number of other reports.
Analyst's Analysis on Arena Pharmaceuticals, Inc. They set a buy rating and a $23.00 price objective for the company. Finally, FBR & Co restated an "outperform" rating and set a $60.00 price target on shares of Arena Pharmaceuticals in a research report on Thursday, March 16th.
Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on Arena Pharma (NASDAQ: ARNA) yesterday and set a price target of $37. Finally, ValuEngine raised shares of Arena Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday. The lowest price target is presently $15 and the analyst with the most aggressive opinion sees the stock going to $50.
Arena Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO Munshi Amit has acquired 2,500 shares of Arena Pharmaceuticals, Inc. The stock was acquired at an average cost of $1.41 per share, with a total value of $70,500.00. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 2,003,235 shares of the stock are valued at $30.51 million. Corporate insiders own 2.14% of the company's stock.
Several institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company's stock worth $118,000 after buying an additional 132 shares during the period. Vanguard Group Inc. now owns 19,905,389 shares of the biopharmaceutical company's stock valued at $29,063,000 after buying an additional 910,434 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Intercept Pharmaceuticals during the first quarter worth approximately $170,000. Over the last quarter, insiders have sold 4,016 shares of company stock valued at $452,624. Tudor Investment Corp Et Al increased its stake in Arena Pharmaceuticals by 200.1% in the fourth quarter. Tudor Investment Corp ET AL now owns 141,225 shares of the biopharmaceutical company's stock valued at $206,000 after buying an additional 68,966 shares during the last quarter. Cantor Fitzgerald assumed coverage on Arena Pharmaceuticals in a research report on Thursday, June 15th. The author does not have any position in the stock mentioned and in no way is recommending to Buy or Sell Arena Pharmaceuticals, Inc. "(ARNA) Receives $38.00 Average Price Target from Analysts" was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another website, it was stolen and reposted in violation of USA and worldwide trademark and copyright legislation. The original version of this story can be viewed at [[permalink]].
Arena Pharmaceuticals (ARNA) opened at 16.52 on Tuesday. 255,704 shares of the company traded hands.
It is now trading at $16.53 which is marginally over $13.12, the stock's 50 day moving average and a tad higher than the 200 day moving average of $14.19. The company has market cap of $489.95 million.
Arena Pharmaceuticals (NASDAQ:ARNA) last issued its quarterly earnings results on Tuesday, May 9th.
Analysts expect Dmc Global Inc (NASDAQ:BOOM) to report $0.03 EPS on July, 27.They anticipate $0.04 EPS change or 400.00% from last quarter's $-0.01 EPS. The company had revenue of $6.60 million for the quarter, compared to analysts' expectations of $4.84 million. Intercept Pharmaceuticals had a negative net margin of 825.58% and a negative return on equity of 116.30%. The business's revenue for the quarter was down 33.0% compared to the same quarter past year. During the same period in the prior year, the firm earned ($0.90) earnings per share. On average, analysts forecast that Arena Pharmaceuticals will post ($3.19) EPS for the current year.
Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases.
